Highest-materiality recent filing
Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook
Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.
Neuronetics announces CFO resignation, 5% workforce reduction, and former CEO consulting deal
Former CEO Keith J. Sullivan enters consulting agreement with release; will vest in equity through March 2027; no additional compensation.
Neuronetics appoints new CEO Dan Reuvers; Q4 revenue $41.8M, net loss $7.2M; FY26 guidance $160-166M
Dan Reuvers appointed President and CEO effective March 23, 2026; base salary $730k, 1.5M RSU grant.
Q4 revenue $41.8M, 23% YoY pro forma growth; NeuroStar revenue $18.3M (+9% pro forma).
Revenue $37.3M (+101% YoY, +11% adjusted pro forma); Greenbrook clinic revenue $21.8M (+25% adj pro forma).
Q2 2025 revenue $38.1M, up 132% YoY; adjusted pro forma growth 18%; net loss $(9.8)M ($0.15 loss per share).
Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance
Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).
Neuronetics Q1 revenue $32M (+84% YoY); narrows FY guidance; CFO to retire March 2026
Q1 revenue $32.0M, up 84% YoY driven by Greenbrook acquisition; net loss $(12.7)M vs $(7.9)M
Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M
Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.
Neuronetics prices $18M public offering of 8M shares at $2.25/share
Gross proceeds ~$18M from 8M shares (plus underwriter option 1.2M shares exercised).
Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).
Neuronetics closes Greenbrook TMS acquisition; adds 2 directors; secures $10M loan amendment.
Acquisition closed Dec 9; exchange ratio 0.01021 Neuronetics share per Greenbrook share; Greenbrook to delist from OTCQB.
Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025
Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).
Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)
Neuronetics reduces workforce by 10%, expects >$3.5M annual cash savings
Workforce reduction of approximately 10% to sharpen focus on growth.
Neuronetics shareholders approve all proposals for Greenbrook acquisition
Charter amendment to increase authorized shares to 250M approved with 16.66M for, 7.33M against.
Ontario court grants interim order for statutory plan of arrangement; Neuronetics to acquire Greenbrook in all-stock transaction.
Neuronetics gets Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
Received Nasdaq letter on Oct 3, 2024; stock closed below $1.00 for 30 consecutive business days.
Neuronetics files investor presentation highlighting benefits of Greenbrook acquisition
Presentation distributed on Oct 2, 2024 detailing strategic rationale and financial benefits of buying Greenbrook TMS Inc.
Neuronetics hosts fireside chat on proposed acquisition of Greenbrook TMS
Neuronetics CEO Keith Sullivan and Greenbrook CEO Bill Leonard discuss deal impact on NeuroStar practices.
Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older
FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.
Neuronetics issues ~25.3M shares to Greenbrook holders; existing Neuronetics shareholders own 57% of combined entity.
Neuronetics to acquire Greenbrook TMS in all-stock deal; Q2 revenue down 7%, net loss widens
Q2 revenue $16.5M (-7% YoY); net loss $(9.8)M ($0.33) vs $(4.9)M ($0.17) prior year.
Neuronetics reports Q2 2024 financial results and proposed combination with Greenbrook TMS
Neuronetics issued a press release on August 12, 2024, announcing unaudited financial results for the three and six months ended June 30, 2024.
Neuronetics enters up to $90M credit facility with Perceptive, replaces SLR debt
Borrowed $50M initial tranche, used $64.6M to repay SLR Investment Corp. loan in full including fees and interest.
Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%
Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.
Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)
FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.
Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow
Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).
On May 6, 2025, the Company announced that Stephen Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Max materiality 0.90 · Median 0.65 · Most common event earnings